Page 153 - 80 guidelines for the treatment of malaria_opt
P. 153
ANNEX 7. Uncomplicated Plasmodium falciparum malaria
No serious imprecision: both limits of the 95% CI imply appreciable benefit with AS+MQ over AQ+SP; at day 14 all participants in both groups had cleared their gametocytes.
Very serious imprecision: there were no serious adverse events in this trial; a trial of this size would be unlikely to detect rare but important serious adverse events.
This comparison has only been reported by one trial from Senegal, which had very few events and no conclusion can be made.
Serious indirectness: only one trial from Senegal reported this outcome; extrapolation of this result to other countries is likely to be unreliable.
Please note that due to its long half-life, treatment failure with AS+MQ may be underestimated at this point in time.
Very serious imprecision: the 95% CI is wide including appreciable benefit and harm with each drug over the other.
AS+MQ may be more effective on gametocytes than AQ+SP (low quality evidence).
Serious limitations: allocation concealment was assessed as “unclear” and no blinding is described.
A7
Very serious imprecision: there were no events in this trial. Children aged <1 year and pregnant or lactating women were excluded.
panel comment: panel conclusion: Senegal (4).
9.
8.
3.
2.
1.
4.
7.
6.
5.
139
